Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens GMMA, 1790GAHBReportar como inadecuado

Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens GMMA, 1790GAHB - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Recently, we developed a high yield production process for outer membrane particles from genetically modified bacteria, called Generalized Modules of Membrane Antigens GMMA, and the corresponding simple two step filtration purification, enabling economic manufacture of these particles for use as vaccines. Using a Shigella sonnei strain that was genetically modified to produce penta-acylated lipopolysaccharide LPS with reduced endotoxicity and to maintain the virulence plasmid encoding for the immunodominant O antigen component of the LPS, scale up of the process to GMP pilot scale was straightforward and gave high yields of GMMA with required purity and consistent results. GMMA were formulated with Alhydrogel and were highly immunogenic in mice and rabbits. In mice, a single immunization containing 29 ng protein and 1.75 ng of O antigen elicited substantial anti-LPS antibody levels. As GMMA contain LPS and lipoproteins, assessing potential reactogenicity was a key aspect of vaccine development. In an in vitro monocyte activation test, GMMA from the production strain showed a 600-fold lower stimulatory activity than GMMA with unmodified LPS. Two in vivo tests confirmed the low potential for reactogenicity. We established a modified rabbit pyrogenicity test based on the European Pharmacopoeia pyrogens method but using intramuscular administration of the full human dose 100 μg of protein. The vaccine elicited an average temperature rise of 0.5°C within four hours after administration, which was considered acceptable and showed that the test is able to detect a pyrogenic response. Furthermore, a repeat dose toxicology study in rabbits using intramuscular 100 μg-dose, intranasal 80 μg-dose, and intradermal 10 μg-dose administration routes showed good tolerability of the vaccine by all routes and supported its suitability for use in humans. The S. sonnei GMMA vaccine is now in Phase 1 dose-escalation clinical trials.

Autor: Christiane Gerke , Anna Maria Colucci, Carlo Giannelli, Silvia Sanzone, Claudia Giorgina Vitali, Luigi Sollai, Omar Rossi, Laura



Documentos relacionados